List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Asia-Pacific Diabetes Care Drugs Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 90 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 90 pages
- Published: 12-06-2019
Market Overview
The Asia-Pacific market for diabetes drugs is estimated to value USD 23.8 billion in 2019, and the market is expected to grow at the CAGR of 4.82%, during the forecast period.
Over the past few decades, Asian countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. Developing countries have more than 70% of the global diabetes population.
The Asian population gets diabetes at a younger age in comparison to the Western population. The reason for this early diabetes development is the sudden change in lifestyle, due to rapid economic growth.
Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia.
Scope of the Report
The Asia-Pacific diabetes drugs report covered by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), and by countries.
Key Market Trends
Oral Anti-Diabetes Drugs Take 67% of the Asia-Pacific Diabetes Drugs Market.
The use of oral anti-diabetes drugs is rising, due to the fact that new generation oral drugs, such as DPP-4 and SGLT-2, reduce the rate of CV risk in diabetes patients.
SGLT-2 and GLP-1 are linked to lowering the mortality rate more effectively than DPP-4 inhibitors.
Meglitinide and sulfonylureas are oral hypoglycemic drugs that directly arouse the discharge of insulin from pancreatic beta cells. They hold a significant market share, of 14.27% and 9.62%, respectively, in the Asia-Pacific anti-diabetics drugs market.
China and Japan Occupy more than a 50% Share in the Asia-Pacific Diabetes Drugs Market.
In the Asia-Pacific region, China and Japan have recognized as potential developing markets, due to the growing diabetic population in this region.
Japan is a mature market, with some associated challenges, like slow economic growth, the aging population, and increased competition. One particular challenge in this region is the growing preference for oral anti-diabetics among type-2 diabetic patients, thereby, leading to a negative insulin volume development.
China has the highest market share and is expected to grow with a steady CAGR of 4%. It also contributes 15% to the global diabetes drugs market.
The country is witnessing a significant increase in the number of generic drug manufacturers. Furthermore, the leading global players in the market studied are facing intense competition from the regional players.
Competitive Landscape
The Asia-Pacific diabetes care drugs market is highly fragmented, with a few major manufacturers gaining presence in major countries of the Asia-Pacific market, while the remaining market comprises other local or region-specific manufacturers.
Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as driving innovations, helping the diabetes drugs market to increase in the Asia-Pacific region. For instance, Biocon has launched its insulin glargine biosimilar, in Japan and Malaysia, partnering with local manufacturers for further commercialization.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Oral Anti-diabetic Drugs
5.1.1.1 Biguanides (Value and Volume 2012-2024)
5.1.1.1.1 Metformin
5.1.1.2 Alpha – Glucosidase Inhibitors (Value and Volume 2012-2024)
5.1.1.2.1 Alpha – Glucosidase Inhibitors
5.1.1.3 Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
5.1.1.3.1 Bromocriptin (Cycloset)
5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
5.1.1.4.1 Invokana (Canagliflozin)
5.1.1.4.2 Jardiance (Empagliflozin)
5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
5.1.1.4.4 Suglat (Ipragliflozin)
5.1.1.5 Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
5.1.1.5.1 Januvia (Sitagliptin)
5.1.1.5.2 Onglyza (Saxagliptin)
5.1.1.5.3 Tradjenta (Linagliptin)
5.1.1.5.4 Vipidia/Nesina (Alogliptin)
5.1.1.5.5 Galvus (Vildagliptin)
5.1.1.6 Sulfonylureas (Value and Volume 2012-2024)
5.1.1.6.1 Sulfonylureas
5.1.1.7 Meglitinides (Value and Volume 2012-2024)
5.1.1.7.1 Meglitinides
5.1.2 Insulin
5.1.2.1 Basal or Long-acting Insulins
5.1.2.1.1 Lantus (Insulin Glargine)
5.1.2.1.2 Levemir (Insulin Detemir)
5.1.2.1.3 Toujeo (Insulin Glargine)
5.1.2.1.4 Tresiba (Insulin Degludec)
5.1.2.1.5 Basaglar (Insulin Glargine)
5.1.2.2 Bolus or Fast-acting Insulins
5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.2.2.2 Humalog (Insulin Lispro)
5.1.2.2.3 Apidra (Insulin Glulisine)
5.1.2.3 Traditional Human Insulins
5.1.2.3.1 Novolin/Actrapid/Insulatard
5.1.2.3.2 Humilin
5.1.2.3.3 Insuman
5.1.2.4 Biosimilar Insulins
5.1.2.4.1 Insulin Glargine Biosimilars
5.1.2.4.2 Human Insulin Biosimilars
5.1.3 Non-insulin Injectable Drugs
5.1.3.1 GLP-1 Receptor Agonists
5.1.3.1.1 Victoza (Liraglutide)
5.1.3.1.2 Byetta (Exenatide)
5.1.3.1.3 Bydureon (Exenatide)
5.1.3.1.4 Trulicity (Dulaglutide)
5.1.3.1.5 Lyxumia (Lixisenatide)
5.1.3.2 Amylin Analogue
5.1.3.2.1 Symlin (Pramlintide)
5.1.4 Combination Drugs
5.1.4.1 Insulin Combinations
5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
5.1.4.2 Oral Combination
5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
5.2 Geography
5.2.1 Asia-Pacific
5.2.1.1 Australia (Value and Volume 2012-2024)
5.2.1.1.1 Oral Anti-diabetic Drugs
5.2.1.1.2 Insulin
5.2.1.1.3 Non-Insulin Injectable Drugs
5.2.1.1.4 Combination Drugs
5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.2 China (Value and Volume 2012-2024)
5.2.1.2.1 Oral Anti-diabetic Drugs
5.2.1.2.2 Insulin
5.2.1.2.3 Non-Insulin Injectable Drugs
5.2.1.2.4 Combination Drugs
5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.3 India (Value and Volume 2012-2024)
5.2.1.3.1 Oral Anti-diabetic Drugs
5.2.1.3.2 Insulin
5.2.1.3.3 Non-Insulin Injectable Drugs
5.2.1.3.4 Combination Drugs
5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.4 Indonesia (Value and Volume 2012-2024)
5.2.1.4.1 Oral Anti-diabetic Drugs
5.2.1.4.2 Insulin
5.2.1.4.3 Non-Insulin Injectable Drugs
5.2.1.4.4 Combination Drugs
5.2.1.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.5 Japan (Value and Volume 2012-2024)
5.2.1.5.1 Oral Anti-diabetic Drugs
5.2.1.5.2 Insulin
5.2.1.5.3 Non-Insulin Injectable Drugs
5.2.1.5.4 Combination Drugs
5.2.1.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.6 Malaysia (Value and Volume 2012-2024)
5.2.1.6.1 Oral Anti-diabetic Drugs
5.2.1.6.2 Insulin
5.2.1.6.3 Non-Insulin Injectable Drugs
5.2.1.6.4 Combination Drugs
5.2.1.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.7 Philippines (Value and Volume 2012-2024)
5.2.1.7.1 Oral Anti-diabetic Drugs
5.2.1.7.2 Insulin
5.2.1.7.3 Non-Insulin Injectable Drugs
5.2.1.7.4 Combination Drugs
5.2.1.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.8 South Korea (Value and Volume 2012-2024)
5.2.1.8.1 Oral Anti-diabetic Drugs
5.2.1.8.2 Insulin
5.2.1.8.3 Non-Insulin Injectable Drugs
5.2.1.8.4 Combination Drugs
5.2.1.8.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.9 Thailand (Value and Volume 2012-2024)
5.2.1.9.1 Oral Anti-diabetic Drugs
5.2.1.9.2 Insulin
5.2.1.9.3 Non-Insulin Injectable Drugs
5.2.1.9.4 Combination Drugs
5.2.1.9.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.10 Vietnam (Value and Volume 2012-2024)
5.2.1.10.1 Oral Anti-diabetic Drugs
5.2.1.10.2 Insulin
5.2.1.10.3 Non-Insulin Injectable Drugs
5.2.1.10.4 Combination Drugs
5.2.1.10.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.11 Rest of Asia Pacific (Value and Volume 2012-2024)
5.2.1.11.1 Oral Anti-diabetic Drugs
5.2.1.11.2 Insulin
5.2.1.11.3 Non-Insulin Injectable Drugs
5.2.1.11.4 Combination Drugs
5.2.1.11.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Takeda
7.1.2 Pfizer
7.1.3 Eli Lilly
7.1.4 Janssen Pharmaceuticals
7.1.5 Astellas
7.1.6 Boehringer Ingelheim
7.1.7 Merck And Co.
7.1.8 AstraZeneca
7.1.9 Bristol Myers Squibb
7.1.10 Novartis
7.1.11 Sanofi
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Oral Anti-diabetic Drugs
Biguanides (Value and Volume 2012-2024)
Metformin
Alpha – Glucosidase Inhibitors (Value and Volume 2012-2024)
Alpha – Glucosidase Inhibitors
Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
Bromocriptin (Cycloset)
Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas (Value and Volume 2012-2024)
Sulfonylureas
Meglitinides (Value and Volume 2012-2024)
Meglitinides
Insulin
Basal or Long-acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Non-insulin Injectable Drugs
GLP-1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination Drugs
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination
Janumet (Sitagliptin and Metformin HCl)
Geography
Asia-Pacific
Australia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
China (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
India (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Indonesia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Japan (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Malaysia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Philippines (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
South Korea (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Thailand (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Vietnam (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Rest of Asia Pacific (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET (2012 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 85 pages | Published: 11-06-2019 |
- Healthcare
- Mordor Intelligence
- 85 pages
- Published: 11-06-2019
Market Overview
The Asia-Pacific blood glucose monitoring market is expected to register a CAGR of 8.83% during the forecast period (2019 – 2024), and the market is estimated to reach USD 2 billion by 2019.
Asia-Pacific has countries with the highest diabetic populations, such as China and India, with an average prevalence rate of more than 8%.
Blood glucose monitoring devices are used for effective diabetes diagnosis and treatment. A rise in the diabetic population drives the market by increasing the use of blood glucose monitoring devices.
Obesity is also considered one of the major factors contributing to the disease condition, mainly type 2 diabetes.
Also, other factors such as technological innovations and advances provide convenience in measuring blood glucose levels. One such advancement in monitoring blood glucose levels was established by continuous glucose monitoring devices.
These devices help in early detection of hypo- and hyperglycemic conditions, which tend to drive the market for glucose monitoring market.
Scope of the Report
The two main types of blood glucose monitoring devices are included in this study. These devices are further categorized into the self-monitoring blood glucose devices [(SMBG) segmented into glucometer devices, test strips, and lancets (which are also studied by their usage in hospital and home use, individually)] and continuous glucose monitoring [(CGM) devices segmented into sensors and receivers].
Key Market Trends
Self-monitoring Blood Glucose Devices Have High Demand
Although CGM is an advanced method for people living with diabetes to check glucose readings in real-time, SMBGs are the most preferred devices by patients in Asia-Pacific, due to their economic affordability and lesser sophistications in usage, when compared to CGM.
The SMBG segment occupies more than 93% of the market share in the Asia-Pacific blood glucose monitoring market. The further segmented market of SMBG uncovers the following understanding, that disposable consumables (test strips and lancets) occupy the largest market share compared to glucometer devices.
China and India rank high in terms of diabetic populations around the globe, and the market for diabetes is expected to increase at a high rate in these two countries during the forecast period.
Although CGM provides real-time data of blood glucose levels for patients, its adaptability is very low in Asia-Pacific markets. The cost factor is a major concern for the low growth of CGM in the Asia-Pacific market.
China Leading the Asia-Pacific Market
China is facing the largest diabetes epidemic in the world, with around 11% of its population suffering from metabolic illness, while nearly 36% are pre-diabetic.
In 2018, China held the largest share in the Asia-Pacific blood glucose monitoring market due to the large patient pool and wide acceptance of advanced technologies.
Competitive Landscape
The Asia-Pacific blood glucose monitoring market is highly fragmented with few major manufacturers having a presence in major countries of the Asia-Pacific market, while the remaining manufacturers stayed confined to the other local or region-specific markets.
Mergers and acquisitions between players in the recent past helped companies strengthen their market presence. For example, Ascensia Diabetes Care (the Swiss tech company, originally formed a few years ago from a merger of Bayer Health’s diabetes division and Panasonic Healthcare) is officially moving into the CGM space via a partnership with Huzhou, China-based Zhejiang POCTech.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Self-monitoring Blood Glucose Devices
5.1.1 By Component (Market Size, Value and Volume)
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.1.2 By End User
5.1.2.1 Hospitals (Market Size, Value and Volume)
5.1.2.1.1 Glucometer Devices
5.1.2.1.2 Test Strips
5.1.2.1.3 Lancets
5.1.2.2 Personal (Market Size, Value and Volume)
5.1.2.2.1 Glucometer Devices
5.1.2.2.2 Test Strips
5.1.2.2.3 Lancets
5.2 Continuous Blood Glucose Monitoring Devices
5.2.1 By Component (Market Size, Value and Volume)
5.2.1.1 Sensors
5.2.1.2 Receivers
5.3 Geography
5.3.1 Asia-Pacific
5.3.1.1 Japan (Market Size, Value and Volume)
5.3.1.1.1 Self-monitoring Blood Glucose Devices
5.3.1.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.1.1.2 By End User (Hospital and Home)
5.3.1.1.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.3.1.1.2 Continuous Glucose Monitoring Devices
5.3.1.1.2.1 By Component (Sensors and Receivers)
5.3.1.1.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
5.3.1.2 South Korea (Market Size, Value and Volume)
5.3.1.2.1 Self-monitoring Blood Glucose Devices
5.3.1.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.2.1.2 By End User (Hospital and Home)
5.3.1.2.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.3.1.2.2 Continuous Glucose Monitoring Devices
5.3.1.2.2.1 By Component (Sensors and Receivers)
5.3.1.2.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
5.3.1.3 China (Market Size, Value and Volume)
5.3.1.3.1 Self-monitoring Blood Glucose Devices
5.3.1.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.3.1.2 By End User (Hospital and Home)
5.3.1.3.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.3.1.3.2 Continuous Glucose Monitoring Devices
5.3.1.3.2.1 By Component (Sensors and Receivers)
5.3.1.3.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
5.3.1.4 India (Market Size, Value and Volume)
5.3.1.4.1 Self-monitoring Blood Glucose Devices
5.3.1.4.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.4.1.2 By End User (Hospital and Home)
5.3.1.4.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.3.1.4.2 Continuous Glucose Monitoring Devices
5.3.1.4.2.1 By Component (Sensors and Receivers)
5.3.1.4.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
5.3.1.5 Australia (Market Size, Value and Volume)
5.3.1.5.1 Self-monitoring Blood Glucose Devices
5.3.1.5.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.5.1.2 By End User (Hospital and Home)
5.3.1.5.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.3.1.5.2 Continuous Glucose Monitoring Devices
5.3.1.5.2.1 By Component (Sensors and Receivers)
5.3.1.5.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
5.3.1.6 Vietnam (Market Size, Value and Volume)
5.3.1.6.1 Self-monitoring Blood Glucose Devices
5.3.1.6.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.6.1.2 By End User (Hospital and Home)
5.3.1.6.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.3.1.6.2 Continuous Glucose Monitoring Devices
5.3.1.6.2.1 By Component (Sensors and Receivers)
5.3.1.6.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
5.3.1.7 Malaysia (Market Size, Value and Volume)
5.3.1.7.1 Self-monitoring Blood Glucose Devices
5.3.1.7.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.7.1.2 By End User (Hospital and Home)
5.3.1.7.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.3.1.7.2 Continuous Glucose Monitoring Devices
5.3.1.7.2.1 By Component (Sensors and Receivers)
5.3.1.7.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
5.3.1.8 Indonesia (Market Size, Value and Volume)
5.3.1.8.1 Self-monitoring Blood Glucose Devices
5.3.1.8.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.8.1.2 By End User (Hospital and Home)
5.3.1.8.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.3.1.8.2 Continuous Glucose Monitoring Devices
5.3.1.8.2.1 By Component (Sensors and Receivers)
5.3.1.8.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
5.3.1.9 Philippines (Market Size, Value and Volume)
5.3.1.9.1 Self-monitoring Blood Glucose Devices
5.3.1.9.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.9.1.2 By End User (Hospital and Home)
5.3.1.9.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.3.1.9.2 Continuous Glucose Monitoring Devices
5.3.1.9.2.1 By Component (Sensors and Receivers)
5.3.1.9.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
5.3.1.10 Thailand (Market Size, Value and Volume)
5.3.1.10.1 Self-monitoring Blood Glucose Devices
5.3.1.10.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.10.1.2 By End User (Hospital and Home)
5.3.1.10.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.3.1.10.2 Continuous Glucose Monitoring Devices
5.3.1.10.2.1 By Component (Sensors and Receivers)
5.3.1.10.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
5.3.1.11 Rest of Asia-Pacific (Market Size, Value and Volume)
5.3.1.11.1 Self-monitoring Blood Glucose Devices
5.3.1.11.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.3.1.11.1.2 By End User (Hospital and Home)
5.3.1.11.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.3.1.11.2 Continuous Glucose Monitoring Devices
5.3.1.11.2.1 By Component (Sensors and Receivers)
5.3.1.11.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Roche
7.1.3 Johnson & Johnson
7.1.4 Dexcom
7.1.5 Medtronic
7.1.6 Arkray
7.1.7 Ascensia Diabetes Care
7.1.8 Agamatrix Inc.
7.1.9 Bionime Corporation
7.1.10 Acon
7.1.11 Medisana
7.1.12 Trivida
7.1.13 Rossmax
7.2 COMPANY SHARE ANALYSIS
7.2.1 Roche
7.2.2 Johnson & Johnson
7.2.3 Abbott Diabetes Care
7.2.4 Dexcom
7.2.5 Medtronics
7.2.6 Others
8 MARKET OPPORTUNITES AND FUTURE TRENDS
MARKET SEGMENTATION
Self-monitoring Blood Glucose Devices
By Component (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
By End User
Hospitals (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
Personal (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
Continuous Blood Glucose Monitoring Devices
By Component (Market Size, Value and Volume)
Sensors
Receivers
Geography
Asia-Pacific
Japan (Market Size, Value and Volume)
Self-monitoring Blood Glucose Devices
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring Devices
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronics and Others)
South Korea (Market Size, Value and Volume)
Self-monitoring Blood Glucose Devices
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring Devices
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronics and Others)
China (Market Size, Value and Volume)
Self-monitoring Blood Glucose Devices
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring Devices
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronics and Others)
India (Market Size, Value and Volume)
Self-monitoring Blood Glucose Devices
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring Devices
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronics and Others)
Australia (Market Size, Value and Volume)
Self-monitoring Blood Glucose Devices
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring Devices
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronics and Others)
Vietnam (Market Size, Value and Volume)
Self-monitoring Blood Glucose Devices
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring Devices
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronics and Others)
Malaysia (Market Size, Value and Volume)
Self-monitoring Blood Glucose Devices
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring Devices
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronics and Others)
Indonesia (Market Size, Value and Volume)
Self-monitoring Blood Glucose Devices
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring Devices
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronics and Others)
Philippines (Market Size, Value and Volume)
Self-monitoring Blood Glucose Devices
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring Devices
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronics and Others)
Thailand (Market Size, Value and Volume)
Self-monitoring Blood Glucose Devices
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring Devices
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronics and Others)
Rest of Asia-Pacific (Market Size, Value and Volume)
Self-monitoring Blood Glucose Devices
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring Devices
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronics and Others)
Artificial Organ Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 119 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 119 pages
- Published: 07-06-2019
Market Overview
The global artificial organ market was valued at USD 29,366.67 million in 2018, and is estimated to be valued at USD 44,899.44 million in 2024, witnessing a CAGR of 7.33%. Factors that are driving the market include the rising geriatric population, scarcity of donor organs, and technological advancements in the artificial organ sector.
Advances in medicine and technology and increased awareness about organ donation and transplantation have contributed to a record number of transplants. But the gap between supply and demand continues. According to the US Government Information on Organ Donation and Transplantation, more than 114,000 patients are on the national transplant waiting list, as of December 2018, and on an average, every 10 minutes, another person is added to the waiting list. 34,770 transplants were performed in 2017, and as of November 2018, a total of 33,431 transplants have been performed in 2018. 95% of US adults support organ donation, but only 54% are actually signed up as donors; only three in 1,000 people die in a way that allows for organ donation. The situation is even direr in countries, such as Japan and South Korea, where the organ donation rates are very low. Hence, the scarcity of donor organs is propelling the demand for artificial organs.
Scope of the Report
An artificial organ is a medical device that is implanted or integrated into the body to replicate or augment the natural function of the organ. As per the scope of the report, artificial organs include implantable devices, such as fully artificial hearts and pacemakers, along with organ support machines, such as dialysis and extracorporeal membrane oxygenation (ECMO) machines.
Key Market Trends
Artificial Kidney is Expected to hold its Highest Market Share in the Organ Type
In the organ type segment of the market, an artificial kidney is believed to have the largest market size and is expected to witness a CAGR of 6.21% during the forecast period.
More than 650,000 patients, per year, in the United States and an estimated 2 million patients worldwide are affected by end-stage renal disease (ESRD). Those who live with ESRD make only 1% of the Medicare-covered population, but account for 7% of the Medicare budget. The number of patients in the United States diagnosed with ESRD is increasing by 5% each year. Mortality rates vary depending on the ESRD treatment. After one year of treatment, those on dialysis have a 20-25% mortality rate, with a five-year survival rate of 35%. People who receive transplants have a 3% mortality rate after five years.
As the rate of mortality because of dialysis is increasing, there is increased demand for artificial kidneys, which is propelling the growth of this segment.
North America Dominates the Market and is Expected to Continue its Dominance in the Forecast Period
North America currently dominates the market for artificial organs, and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to increased demand for artificial organs. The United States spends a significant parentage of its GDP each year on healthcare. According to the recent report of the Organization for Economic Co-operation and Development (OECD), 2018, about 18% of the GDP is spent on healthcare. Out of this, a substantial part goes into transplants being performed in the United States. Therefore, the United States holds the largest share in the artificial organ market in the North American region.
Competitive Landscape
The artificial organ market is moderatley competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies with less prices. Companies, like B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corporation, Getinge AB, and Medtronic PLC, hold the substantial share in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Rising Geriatric Population
4.3.2 Scarcity of Donor Organs
4.3.3 Technological Advancements in the Artificial Organ Sector
4.4 Market Restraints
4.4.1 Expensive Procedures
4.4.2 Risks Associated With Artificial Organs
4.5 Industry Attractiveness – Porter’s Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers/Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products
4.5.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Organ Type
5.1.1 Artificial Heart
5.1.1.1 Prosthetic Heart Valves
5.1.1.2 Ventricular Assist Devices
5.1.1.3 Cardiac Pacemakers
5.1.2 Artificial Kidney
5.1.3 Artificial Pancreas
5.1.4 Artificial Lungs
5.1.5 Cochlear Implants
5.1.6 Other Organ Types
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 B. Braun Melsungen AG
6.1.2 Baxter International Inc.
6.1.3 Boston Scientific Corporation
6.1.4 Getinge AB
6.1.5 Medtronic PLC
6.1.6 Abiomed
6.1.7 Asahi Kasei Medical Co. Ltd
6.1.8 Berlin Heart GmbH
6.1.9 Carmat SA
6.1.10 Edward Lifesciences Corporation
6.1.11 Jarvik Heart Inc.
6.1.12 Terumo Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Organ Type
Artificial Heart
Prosthetic Heart Valves
Ventricular Assist Devices
Cardiac Pacemakers
Artificial Kidney
Artificial Pancreas
Artificial Lungs
Cochlear Implants
Other Organ Types
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Apheresis Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and associated safety, technological advancement in the development of new apheresis techniques, and rise in the reimbursement policies and funding for apheresis procedures. Due to the aforementioned factors, the apheresis market is expected to experience a boost during the forecast period.
With the increasing number of surgeries and surgical techniques, advanced treatments have led to global demand for blood and the blood components. The need for blood components is significantly growing and contributing to healthcare spending. Apheresis has also recently witnessed a high demand due to an increased number of patients suffering from various ailments related to blood, kidney, metabolic diseases, and neurological disorders. Therefore, apheresis technology is used to reduce the number of white cells, until other medications can control them. With the steady increase in the number of patients suffering from these diseases, ailments, and the technical ease of using these devices in the treatment of these diseases, requiring a minimal hospital stay, the global apheresis market is poised to experience growth during the forecast period.
The use of apheresis in clinically ill patients is increasing day by day, and it has been widely used as the primary therapy or as an adjunct to other treatments for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure.
Therefore with the steady increase in the number of patients suffering from these diseases, ailments, and the technical ease of using these devices in the treatment of these diseases, thus requiring a minimal hospital stay, the global apheresis market is poised to experience growth during the forecast period.
The Scope of the Report
As per the scope of the report, apheresis is a medical technique where the blood of an individual, be a donor or a patient, is passed through an apparatus that segregates out a particular constituent and returns the rest to the blood circulation. It involves blood purification and blood component separation by using centrifugation or membrane filtration technology. This procedure is performed for blood donation component or for the treatment of disease.
Key Market Trends
Hematological Disorders is the Segment under Application that is Expected to Grow Fastest during the Forecast Period
Hematological disorders are found common in low-income countries, and they make a substantial contribution to morbidity and mortality of individuals in these regions. Hence, owing to the increasing burden of hematological incidences and growing applications of apheresis as a treatment method for hematological disorders, the apheresis market for hematological disorders is expected to experience growth in the forecast period.
The recent years brought about a rise in new options of therapeutic apheresis, such as immunoadsorption, double filtration and cytapheresis used in the treatment of both primary and secondary autoimmune renal diseases. Those methods, more selective and safer than the classic TA, are potentially more efficient in the removal of pathogens, thus reducing the intoxication of the patient’s organism.
Asia-Pacific holds the Fastest Growth and is Expected to follow the Same Trend over the Forecast Period
The Asia-Pacific region is predicted to witness high growth, owing to the rising geriatric population and the increasing prevalence of several choric diseases. China is found to be one of the largest consumers and manufacturers in the global plasma-derived products market and serves a vast population. Great progress has been made in the Chinese plasma fractionation industry in the past 50 years. Moreover, increasing healthcare expenditure is another critical factor that is likely to enhance the growth of the market in the near future.
Competitive Landscape
The market studied is dominated by a few major players, and currently, the market is well established in many areas and has shown nascent success history. However, its full potential is yet to be determined in the developing regions. With increasing government initiatives, there is an awareness among people, which is further driving the growth of the market studied.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Disease Burden
4.2.2 Rise in Demand for Blood Components and Associated Safety
4.2.3 Technological Advancement in Development of New Apheresis Techniques
4.2.4 Rise in the Reimbursement Policies and Funding for Apheresis Procedures
4.3 Market Restraints
4.3.1 High Capital Investment and Costs Associated with Apheresis Procedures
4.3.2 Lack of Qualified Skilled Professionals
4.3.3 Risk of Blood Contamination
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Product
5.1.1 Devices
5.1.2 Disposables
5.1.2.1 Interventional/Surgical Simulators
5.2 By Apheresis Procedure
5.2.1 Leukapheresis
5.2.2 Plasmapheresis
5.2.3 Plateletpheresis
5.2.4 Erythrocytapheresis
5.2.5 Other Apheresis Procedures
5.3 By Technology
5.3.1 Centrifugation
5.3.2 Membrane Separation
5.4 By Application
5.4.1 Renal Disorders
5.4.2 Hematological Disorders
5.4.3 Neurological Disorders
5.4.4 Autoimmune Disorders
5.4.5 Other Applications
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Asahi Kasei Corporation
6.1.2 B. Braun Melsungen AG
6.1.3 Cerus Corporation
6.1.4 Fresenius SE & Co. KGaA
6.1.5 Haemonetics Corporation
6.1.6 HemaCare Corporation
6.1.7 Kaneka Corporation
6.1.8 Kawasumi Laboratories Inc.
6.1.9 Terumo Corporation
6.1.10 Therakos Inc.
7. Market Opportunities and Future Trends
Market Segmentation
- By Product
Devices
Disposables
Interventional/Surgical Simulators
By Apheresis Procedure
Leukapheresis
Plasmapheresis
Plateletpheresis
Erythrocytapheresis
Other Apheresis Procedures
By Technology
Centrifugation
Membrane Separation
By Application
Renal Disorders
Hematological Disorders
Neurological Disorders
Autoimmune Disorders
Other Applications
Geography
North America
United States
Canada
Mexico - Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Antidepressant Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 112 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 112 pages
- Published: 07-06-2019
Market Overview
The major factors for the growth of the global antidepressant market include the rising cases of depression, increasing awareness about depression, and the emergence of novel biologics.
Globally, more than 300 million people across all age groups suffer from depression, and this number is rising at a fast pace. The increase in the number of young adults affected by some form of depression is as high as 8%. Depression due to factors, such as social isolation and stressful work environment has contributed the most toward increasing the number of people suffering from depression. The number of people falling prey to depression and related disorders is expected to continue to increase, as a result of improper eating habits, stressful work schedule, increasing isolation from family and loved ones due to technology, and the inability to adapt to the rapid pace, at which, the world is moving forward. In countries, such as the United Kingdom and the United States, which are characterized by their fast-paced economies, the percentage of ‘affected population’ in every age group is quite high. In addition, increasing aged population across the world enhances the potential of the market studied over the forecast period. According to the estimates of WHO, in 2015, 322 million people were suffering from depression, globally, and nearly half the number of these people belong to the Southeast Asian region and the Western Pacific region. Thus, the rising cases of depression across the world are expected to drive the overall growth of the market studied over the forecast period.
Scope of the Report
As per the scope of the report, antidepressant drugs are used for the treatment of major depressive disorders and other conditions, including dysthymia, anxiety disorders, obsessive-compulsive disorder (OCD), eating disorders, chronic pain, neuropathic pain, etc. The market is segmented by type of product, depressive disorder, and geography.
Key Market Trends
Major Depressive Disorder Segment by Depressive Disorder is Expected to Account for the Largest Market Share During the Forecast Period
The major depressive disorder possible causes comprise of the combination of biological, psychological, and social sources of distress. The major risk factors include family history, significant life changes, certain medications, chronic health problems, and substance abuse. As per the data published by the National Institute of Mental Health, an estimated 16.2 million adults in the United States had at least one major depressive episode. This number represented 6.7% of all US adults and is majorly prevalent in women as compared to men. Most commonly, selective serotonin reuptake inhibitors (SSRI) are used in the treatment of major depression, while there are some therapies available to normalize brain changes associated with depression. Thus, owing to the rising number of the patient pool, the market is expected to witness high growth over the forecast period.
North America accounted for the Largest Share in the Global Market
The increasing cases of depression is one of the major factors that is expected to drive the overall growth of the US antidepressant market over the forecast period. Moreover, there is a rise in the geriatric population in the United States, which is expected to create more opportunities for market players in the region. Women are twice as likely to be affected by generalized anxiety disorder (GAD) when compared to men. Six million adults, or 2.7% of the US population suffer from panic disorders, and around 2.2 million or 1.0% of the US population suffer from obsessive-compulsive disorder (OCD), which is found to be equally common among men and women. The two major factors leading to the rise in the consumption of antidepressants are the course of the treatment lasting longer than it used to be, and the antidepressants that are currently being prescribed are not only for severe depression, but also for mild depression, anxiety, social phobia, and more. The increasing prevalence of disorders and increasing rate of consumption of antidepressants are expected to drive the market studied during the forecast period.
Competitive Landscape
The market studied comprises of a combination of multinational and domestic players. The entry barriers are comparatively less, and most of the drugs are available over the counter. The companies are trying to expand their geographical presence by partnerships or acquisitions. Some of the key players in the market are Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, and Pfizer Inc.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Cases of Depression
4.2.2 Increasing Awareness about Depression
4.2.3 Emergence of Novel Biologics
4.3 Market Restraints
4.3.1 Preference of Non-pharmacological Therapies over Pharmacological Therapies
4.3.2 Side-effects and Patent Expiry of Antidepressant Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Selective Serotonin Reuptake Inhibitor (SSRI)
5.1.2 Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
5.1.3 Tricyclic Antidepressant (TCA)
5.1.4 Monoamine Oxidase Inhibitor (MAOI)
5.1.5 Other Products
5.2 By Depressive Disorder
5.2.1 Major Depressive Disorder
5.2.2 Obsessive-compulsive Disorder (OCD)
5.2.3 Generalized Anxiety Disorder (GAD)
5.2.4 Panic Disorder (PD)
5.2.5 Other Depressive Disorders
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan PLC
6.1.2 AstraZeneca
6.1.3 Eli Lilly and Company
6.1.4 GlaxoSmithKline PLC
6.1.5 H. Lundbeck AS
6.1.6 Johnson & Johnson
6.1.7 Merck & Co. Inc.
6.1.8 Pfizer Inc.
6.1.9 Sanofi
6.1.10 Sun Pharmaceuticals Pvt Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
Tricyclic Antidepressant (TCA)
Monoamine Oxidase Inhibitor (MAOI)
Other Products
By Depressive Disorder
Major Depressive Disorder
Obsessive-compulsive Disorder (OCD)
Generalized Anxiety Disorder (GAD)
Panic Disorder (PD)
Other Depressive Disorders
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Antibiotics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 07-06-2019
Market Summary
The global antibiotics market was valued at USD 42,653.89 million in 2018, and is estimated to be valued at USD 56,369.92 million in 2024, witnessing a CAGR of 4.7%. Certain factors that are driving the market growth include the emergence of anti-MRSA drugs, development of generic drugs, and vulnerable aging population.
A company that initially produced the patented drug tries to generate maximum revenue before the patent expires. Once the patent expires, there will be many competitors who begin manufacturing the generic formulations. They have the same composition and same pharmacological activities as of the original drug. Almost 80% of the prescription antibiotics are generic. As a result of this, the price is reduced. More people can afford drugs, thus, resulting in improved healthcare outcomes. However, indiscriminate drug usage also leads to drug resistance and other complications.
Scope of the Report
As per the scope of the report, antibiotic medicines are among the most prescribed courses worldwide, in fighting bacterial infections, primarily in outpatient settings.
Key Market Trends
Carbapenems are Expected to Show the Rapid Growth of in the Future.
The cephalosporin segment is expected to account for the largest market size during the forecast period. Carbapenems are expected to witness the highest CAGR of around 5.9% during the forecast period.
The rising threat of drug resistance and a weak pipeline of new molecules are leading to the development of combinational formulations. For instance, in countries, like India, the emergence of multi-drug-resistant tuberculosis (TB) is a major factor driving the R&D expenditures. Methicillin-resistant Staphylococcus aureus (MRSA) is another bacterium responsible for several infections in humans that are difficult to treat. The MRSA infection is difficult to treat with standard antibiotics, such as penicillins (methicillin, dicloxacillin, nafcillin, and oxacillin), and the cephalosporins. In 2014, the US Food and Drug Administration (FDA) approved four new antibiotics for the treatment of infections caused by gram-positive bacteria, including MRSA.
North America is Expected to Dominate the Market in the Forcasted Period
North America currently dominates the market for antibiotics and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased adoption of antibiotics. The United States holds the majority of the market in the North American region, due to the fact that the United States has the highest antibiotic prescribing rate in the North American region. In addition, there is a rise in per capita health expenditure in the country, which is expected to increase over the forecast period, owing to decrease in the unemployment rate.
Competitive Landscape
The antibiotics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products with less prices. Companies, like Glaxosmithkline, Pfizer PLC, Bayer AG, Novartis AG, and Abbott Inc., hold significant market shares in the antibiotics market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Emergence of Anti-MRSA/VRE Drugs
4.2.2 Development of Generic Drugs
4.2.3 Vulnerable Aging Population
4.3 Market Restraints
4.3.1 Antibiotic Resistance
4.3.2 Fewer Companies Involved in Active Research
4.3.3 Time Taken for Regulatory Approval
4.4 Industry Attractiveness of Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Cephalosporins
5.1.2 Penicillins
5.1.3 Fluroquinilones
5.1.4 Macrolides
5.1.5 Carbapenems
5.1.6 Aminoglycosides
5.1.7 Sulfonamides
5.1.8 Other Product Types
5.2 By Spectrum
5.2.1 Broad-spectrum Antibiotics
5.2.2 Narrow-spectrum Antibiotics
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 France
5.3.2.2 Germany
5.3.2.3 United Kingdom
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithKline PLC
6.1.2 Johnson & Johnson Inc.
6.1.3 Merck & Co. Inc.
6.1.4 Pfizer Inc.
6.1.5 Bayer Healthcare AG
6.1.6 Novartis AG
6.1.7 Sanofi SA
6.1.8 Abbott Laboratories
6.1.9 Roche Holding AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Cephalosporins
Penicillins
Fluroquinilones
Macrolides
Carbapenems
Aminoglycosides
Sulfonamides
Other Product Types
By Spectrum
Broad-spectrum Antibiotics
Narrow-spectrum Antibiotics
Geography
North America
United States
Canada
Mexico
Europe
France
Germany
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America